Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15777509 | 1.00 | CYP1A2 (0.67) | CYP1A2CYP2C19MAPTHPGDALOX12 | |
| SCHEMBL5946413 | 0.85 | RAB9A (0.61) | CYP1A2CYP2C19MAPTHPGDALOX12 | |
| SCHEMBL30714430 | 0.85 | MAPT (0.62) | CYP1A2CYP2C19MAPTHPGDALOX12 | |
| SCHEMBL23610389 | 0.85 | MAPT (0.62) | CYP1A2CYP2C19MAPTHPGDALOX12 | |
| SCHEMBL6990314 | 0.83 | CES2 (0.64) | CYP1A2MAPTHPGDALDH1A1HTT | |
| SCHEMBL6990311 | 0.83 | CES2 (0.64) | CYP1A2MAPTHPGDALDH1A1HTT | |
| SCHEMBL3606864 | 0.83 | MAPT (0.76) | CYP1A2CYP2C19MAPTHPGDALOX12 | |
| SCHEMBL12275069 | 0.83 | ALDH1A1 (0.59) | CYP1A2CYP2C19MAPTHPGDALOX12 | |
| SCHEMBL12275071 | 0.83 | ALDH1A1 (0.59) | CYP1A2CYP2C19MAPTHPGDALOX12 | |
| SCHEMBL3606868 | 0.83 | MAPT (0.76) | CYP1A2CYP2C19MAPTHPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763367-A1 | PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2928471-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10173996-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-2443132-B1 | PLATINUM (II) ISOQUINOLINE-PYRIDINE-BENZENE BASED COMPLEXES, PREPARING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DIODES MADE THEREFROM | VERSITECH LTD (CN) | 2018-10-10 | — | — | EP | disclosed |
| US-9908865-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170275266-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-9714230-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170158664-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-9604961-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160347733-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9458129-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160068507-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160002201-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2928471-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2015-10-14 | — | — | EP | disclosed |
| US-9107916-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150164872-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8987461-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140194469-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014089364-A1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS, INC (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20100314994-A1 | Platinum (II) Isoqulinoline-Pyridine-Benzene Based Complexes, Methods for Making Same, and Organic Light-Emitting Diodes Including Such Complexes | VERSITECH LIMITED (CN) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10173996-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | CYP1A2 1218/4885CYP2C19 1607/4885MAPT 2204/4885 |
| US-20160002201-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | CYP1A2 1218/4885CYP2C19 1607/4885MAPT 2204/4885 |
| US-20170275266-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | CYP1A2 1218/4885CYP2C19 1607/4885MAPT 2204/4885 |
| US-20160347733-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | CYP1A2 1218/4885CYP2C19 1607/4885MAPT 2204/4885 |
| US-20100314994-A1 | Platinum (II) Isoqulinoline-Pyridine-Benzene Based Complexes, Methods for Making Same, and Organic Light-Emitting Diodes Including Such Complexes | OCIAD2, PDCD1LG2, PDCD2L | CYP1A2 893/4885CYP2C19 1534/4885MAPT 596/4885 |
| US-20160068507-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | CYP1A2 1218/4885CYP2C19 1607/4885MAPT 2204/4885 |
| US-20170158664-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | CYP1A2 1218/4885CYP2C19 1607/4885MAPT 2204/4885 |
| US-20150164872-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | CYP1A2 1218/4885CYP2C19 1607/4885MAPT 2204/4885 |
| US-20140194469-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | CYP1A2 1218/4885CYP2C19 1607/4885MAPT 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.